COLOSSAL BIOSCIENCES
Tokenised Economic Right (not equity) to potential future liquidity from WLTH’s (Metamasters DAO Corp) allocation in Colossal Biosciences Inc. Slices are not securities of, nor endorsed by, the underlying company. They are unsecured contractual rights against WLTH (Metamasters DAO Corp). Residents of the U.S., UK, EU, and other restricted jurisdictions are ineligible. Review the full Terms & Conditions before purchasing.
Category: Biotechnology, Synthetic Biology & Conservation Genomics Stage: Late-stage private (Series C) Opportunity Type: Tokenised Economic Right
Company Overview
Colossal Biosciences Inc. is a biotechnology and computational biology company focused on developing a platform for de-extinction, genetic rescue, and conservation genomics. Founded in 2021, the company integrates CRISPR gene editing, reproductive technologies, and large-scale bioinformatics to engineer genetic outcomes that extend beyond individual species projects. While best known for high-profile de-extinction initiatives, Colossal positions itself as a broader synthetic biology infrastructure company with multiple downstream commercialization paths. As of January 2025, Colossal has raised approximately $435 million in total funding and was valued at $10.2 billion following its Series C round. The company remains privately held and continues to expand research operations, partnerships, and platform capabilities.
The Problem
Accelerating global biodiversity loss with limited tools for genetic recovery. Traditional conservation methods cannot restore lost genetic diversity or extinct genomes. Endangered species suffer from inbreeding and irreversible genetic bottlenecks. Large-scale genomic engineering infrastructure is scarce and capital intensive. Slow, fragmented translation of cutting-edge genomics into real-world deployment.
The Solution
CRISPR-based genomic editing to reconstruct extinct or endangered species’ DNA using close living relatives. Advanced reproductive technologies to support gestation and viability of engineered embryos. Computational biology and AI-driven platforms to design, simulate, and validate genomic outcomes at scale. Spin-out companies commercializing biotech tools, software, and applied genomic technologies. Conservation-focused deployment through partnerships and affiliated foundation initiatives.
Founding Team
Ben Lamm – Founder & CEO; serial entrepreneur with experience in technology and biotechnology ventures. Dr. George Church – Co-Founder; Harvard geneticist and pioneer in genome sequencing and synthetic biology. Dr. Beth Shapiro – Chief Science Officer; expert in ancient DNA, evolutionary genomics, and de-extinction science.
Business Model
Technology licensing of proprietary genomic editing and computational biology platforms. Commercial spin-outs in biotech, software, and environmental genomics. Research grants, strategic partnerships, and institutional collaborations. Long-term potential biological products subject to regulatory approval pathways.
Traction and Validation
$200M Series C financing led by TWG Global (Mark Walter & Thomas Tull) announced January 2025. Reported post-money valuation of ~$10.2B. Total capital raised of ~$435M since launch. Team of ~170+ scientists across multiple global research facilities. High-profile projects including the woolly mammoth, dire wolf, dodo, and thylacine. Acquisitions of ViaGen Pets and the Thylacine Integrated Genomics Restoration Research Lab. Ongoing partnerships with conservation organizations and research institutions.
Intellectual Property and Strategic Assets
Owned: Proprietary CRISPR-based genomic editing, reproductive, and cloning technologies. Owned: Computational biology and AI platforms for large-scale genome design and analysis. Strategic Assets: Acquired cloning and genomics infrastructure through targeted acquisitions. Network Effects: Deep scientific partnerships and conservation collaborations globally. Data: Extensive genomic datasets spanning extinct, endangered, and engineered species.
Disclaimer
No affiliation — nominative reference only.
The underlying company is entirely unaffiliated with this offering, with Metamasters DAO Corp, and with the associated Slices. Specifically:
No endorsement or authorisation. The underlying company has not reviewed, approved, authorised, endorsed, sponsored, or consented to any aspect of this token, marketing material, or structure.
No participation or cooperation. The underlying company and its officers, directors, shareholders, and employees are not involved—directly or indirectly—in structuring, issuing, marketing, managing, servicing, or redeeming the Slices.
No contractual or economic relationship. Purchasing a Slice does not give you any equity, debt, contractual claim, option, warrant, or other right against the underlying company. Your sole counter-party is WLTH.
No obligations on the underlying company. It owes you no fiduciary duty, payment, or disclosure and will have no liability to you in connection with your purchase.
No effect on the underlying company’s securities. Issuing Slices does not affect its capitalisation, shareholder base, voting power, or governance.
Trademark usage. Any mention of the underlying company’s name is strictly nominative. WLTH claims no ownership and implies no sponsorship.
Last updated